108 related articles for article (PubMed ID: 15523935)
1. [Subjective and objective evaluation of olanzapine treatment in schizophrenia].
Jarema M; Murawiec S; Tafliński T
Psychiatr Pol; 2004; 38(5):895-909. PubMed ID: 15523935
[TBL] [Abstract][Full Text] [Related]
2. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
3. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being.
Kluge M; Wehmeier PM; Dittmann RW; Langer F; Czekalla J; Lehmann M; Kessler FH; Beyenburg S; Naber D
Pharmacopsychiatry; 2005 Jan; 38(1):6-12. PubMed ID: 15706459
[TBL] [Abstract][Full Text] [Related]
4. [Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].
Meder J; Debowska G; Lis J; Araszkiewicz A; Sierosławska K; Kolesaric A; Treuer T
Psychiatr Pol; 2004; 38(3):469-84. PubMed ID: 15199656
[TBL] [Abstract][Full Text] [Related]
5. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
[TBL] [Abstract][Full Text] [Related]
6. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
[TBL] [Abstract][Full Text] [Related]
7. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.
Naber D; Riedel M; Klimke A; Vorbach EU; Lambert M; Kühn KU; Bender S; Bandelow B; Lemmer W; Moritz S; Dittmann RW
Acta Psychiatr Scand; 2005 Feb; 111(2):106-15. PubMed ID: 15667429
[TBL] [Abstract][Full Text] [Related]
8. LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment.
Pietrini F; Spadafora M; Tatini L; Talamba GA; Andrisano C; Boncompagni G; Manetti M; Ricca V; Ballerini A
Eur Psychiatry; 2016 Sep; 37():35-42. PubMed ID: 27442981
[TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
Hofer A; Rettenbacher MA; Edlinger M; Huber R; Bodner T; Kemmler G; Sachs G; Fleischhacker WW
Pharmacopsychiatry; 2007 Jan; 40(1):1-8. PubMed ID: 17327953
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
[TBL] [Abstract][Full Text] [Related]
13. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
Lecrubier Y; Quintin P; Bouhassira M; Perrin E; Lancrenon S
Acta Psychiatr Scand; 2006 Nov; 114(5):319-27. PubMed ID: 17022791
[TBL] [Abstract][Full Text] [Related]
14. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.
Shaw P; Sporn A; Gogtay N; Overman GP; Greenstein D; Gochman P; Tossell JW; Lenane M; Rapoport JL
Arch Gen Psychiatry; 2006 Jul; 63(7):721-30. PubMed ID: 16818861
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
Silva de Lima M; de Jesus Mari J; Breier A; Maria Costa A; Pondé de Sena E; Hotopf M
J Clin Psychiatry; 2005 Jul; 66(7):831-8. PubMed ID: 16013897
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine treatment of residual positive and negative symptoms.
Buchanan RW; Ball MP; Weiner E; Kirkpatrick B; Gold JM; McMahon RP; Carpenter WT
Am J Psychiatry; 2005 Jan; 162(1):124-9. PubMed ID: 15625210
[TBL] [Abstract][Full Text] [Related]
17. Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis.
Peuskens J; Porsdal V; Pecenak J; Handest P; D'yachkova Y; Brousil R; Deberdt W
BMC Psychiatry; 2012 Aug; 12():130. PubMed ID: 22935168
[TBL] [Abstract][Full Text] [Related]
18. Switching depot antipsychotic drug responders to oral olanzapine.
Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch N; Stikovac D; Lewis S
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):141-4. PubMed ID: 15610956
[TBL] [Abstract][Full Text] [Related]
19. Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching.
Italiano D; Bruno A; Santoro V; Lanza G; Muscatello MR; Zoccali R; Spina E
Ther Drug Monit; 2015 Dec; 37(6):827-30. PubMed ID: 25830930
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
